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Abstract
Introduction: K2p3.1, also known as TASK‐1, is a twin‐pore acid‐sensitive repolarizing
K+ channel, responsible for a background potassium current that significantly
contributes to setting the resting membrane potential of cardiac myocytes. Inhibition
of IK2p3.1 alters cardiac repolarization and is proarrhythmogenic. In this study, we
have examined the expression of K2p3.1 and function of this channel in tissue and
myocytes from across the left ventricular free wall.
Methods and Results: Using fluorescence immunocytochemistry, the expression of
K2p3.1 protein in myocytes from the subendocardial region was found to be twice
(205% ± 13.5%) that found in myocytes from the subepicardial region of the left
ventricle (100% ± 5.3%). The left ventricular free wall exhibited a marked transmural
gradient of K2p3.1 protein expression. Western blot analysis confirmed significantly
higher K2p3.1 protein expression in subendocardial tissue (156% ± 2.5%) than
subepicardial tissue (100% ± 5.0%). However, there was no difference in K2p3.1
messenger RNA expression. Whole‐cell patch clamp identified IK2p3.1 current density
to be significantly greater in myocytes isolated from the subendocardium (7.66 ± 0.53
pA/pF) compared with those from the subepicardium (3.47 ± 0.74 pA/pF).
Conclusions: This is the first study to identify a transmural gradient of K2p3.1 in the
left ventricle. This gradient has implications for understanding ventricular arrhyth-
mogenesis under conditions of ischemia but also in response to other modulatory
factors, such as adrenergic stimulation and the presence of anesthetics that inhibits
or activates this channel.
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1 | INTRODUCTION
K2p3.1 (TWIK‐related acid‐sensitive K+ channel; GenBank accession
number AF031384, rattus) alternatively known as “TASK‐1,” is a member
of the twin‐pore K+ channel family, comprising four transmembrane
segments and two pore‐forming domains with intracellular termini.
Duprat et al1 first described the properties of K2p3.1 as a background
conductance channel with instantaneous activation and a current‐voltage
relationship that indicated an openly rectifying, K+ selective, pore
function. The principal modifier of K2p3.1 channel functionality is
considered to be external pH with the channel showing a dynamic
functional response within the normal physiological range, with maximal
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activation at pH more than 7.8 but complete inhibition at pH values less
than 6.4.1–3 The pK of the channel is ~7.3 with a Hill coefficient of ~1.6,
thus showing a steep sensitivity to pH across this key physiological and
pathophysiological range.1 Channel functionality of K2p3.1 can also be
modulated by several other factors: inhibition occurs during hypoxia, in
response to α adrenergic4 and endothelin‐1 receptor stimulation5 and in
the presence of the endocannabinoid anandamide (or its stable analog
methanandamide).6,7 It also shows phosphorylation‐dependent inhibition
by protein kinase C7 and inhibition by platelet activating factor.8 In
contrast, activation of K2p3.1 channels occurs in response to the key
inhalational anesthetics halothane, sevoflurane, and isoflurane.4,9 The
broad spectrum of intrinsic and extrinsic factors that dynamically
modulate this channel make this an important target of interest for
understanding the response of the cardiac action potential to numerous
stressors and conditions.
K2p3.1 protein has been demonstrated to be present in both the
atria and ventricles of the heart.2,10,11 In myocytes derived from
human atria samples, IK2p3.1 has been shown to contribute significantly
to repolarization of the myocyte and constitutes approximately 40% of
the background potassium current.12 Inhibition or complete genetic
knockout of K2p3.1 channels in the mouse heart causes a significant
prolongation of the ventricular action potential duration (APD) (by
approximately 17%) and an increase in QTc and QRS intervals (by
approximately 30% each).13,14 In ventricular myocytes, similarly to
atrial myocytes, IK2p3.1 contributes to repolarization and shortening of
the APD.15,16 This impact has been demonstrated to vary between
cells with Putzke et al,16 suggesting this may be due to variation in the
specific origin of the myocytes in such pooled cell preparations and
their associated action potential characteristics. Within this study,
they were able to model the impact of current through K2p3.1 using
the “Pandit” mathematical model of the rat ventricular subepicardial
myocyte,17 identifying a predicted significant prolongation of the APD
if this current were inhibited in myocytes from this region.16 No
previous investigations have, however, directly investigated potential
heterogeneity of IK2p3.1 expression within the ventricular wall. Such
heterogeneity would have implications for understanding the response
of the heart to the numerous changes altering the activity of this
channel and its associated current. Our hypothesis was, therefore, that
a heterogeneous expression pattern of K2p3.1 and associated current
exists within the left ventricular free wall. Such a difference would
have the potential to impact the dispersion of repolarization across the
wall of the heart in the event of changes in pH and many other
physiological and pathological signals, predisposing to arrhythmias.
2 | MATERIALS AND METHODS
2.1 | Acquisition of tissue and single myocytes
Male Wistar rats aged 5 to 6 months were humanely killed via
concussion followed by cervical dislocation. All work was performed in
accordance with the Animals (Scientific Procedures) Act 1986 and
approved by local ethics committees. Each heart was dissected to
remove the left ventricular free wall. The cross‐section of the ventricular
wall for immunocytochemistry was oriented in cryomedia and snap
frozen in isopentane cooled by liquid nitrogen. For Western blot analysis
and messenger RNA (mRNA) analysis the left ventricular free wall was
dissected into the subepicardial and subendocardial layers (~30% of the
total wall thickness from each surface), the midlayer and outer
endothelium layers were discarded; regional tissue samples were frozen
in liquid nitrogen and stored at −80°C until used.
The preparation of subepicardial and subendocardial single myocytes
used a variation of a method previously described by Harrison et al.18
Briefly, each heart was perfused via the aorta with a 4‐(2‐hydroxyethyl)‐
1‐piperazineethanesulfonic acid (HEPES)‐buffered saline solution con-
taining (mM): NaCl, 130; KCl, 5.4; MgCl2, 1.4; NaH2PO4, 0.4; HEPES, 5;
glucose, 10; creatine, 10; taurine, 20; adjusted to pH 7.4 using NaOH and
bubbled with 100% O2. All solutions were maintained at 35°C. Initially,
the perfusate also contained 0.75mM CaCl2 but once the heart
was clear of blood (1minute of perfusion) the perfusate was changed
to a 0mM Ca2+ version of the saline solution also containing
0.1mM ethylene glycol‐bis(β‐aminoethyl ether)‐N,N,N′,N′‐tetraacetic
acid (EGTA). After 4minutes perfusion the solution was supplemented
with Type 1 collagenase (Worthington Biochemical Corp., Lakewood,
NJ), 0.8mg/mL and protease type XIV (Sigma‐Aldrich, Dorset, UK)
0.1U/mL for 6minutes of perfusion. The heart was then removed from
the aortic cannula, the left ventricular free wall removed and was
dissected into the subepicardial and subendocardial layers. The isolated
regions were agitated in the basic saline solution supplemented with
10% horse serum to disperse single myocytes. The resultant suspension
of cells was centrifuged at 300 rpm to form a pellet and resuspended in a
fresh solution containing 0.2mM Ca2+ for storage until use.
2.2 | Analysis of protein expression
For immunofluorescence, as previously described by Jones et al,10 single
myocytes and tissue cryosections of 10 µm thickness were fixed using 4%
paraformaldehyde in phosphate‐buffered saline (PBS) for 20minutes,
followed by washing. Myocytes and tissue were immersed in Triton
X‐100, 0.05% in PBS for 20minutes, followed by further washing. After
1 hour in a blocking solution containing 20% horse serum and 0.1%
bovine serum albumin an anti‐K2p3.1 primary antibody (rabbit polyclonal;
Alomone, Jerusalem, Israel) was applied at 1:200 diluted in blocking
solution and incubated overnight at 4°C. After washing to remove excess
antibody, Alexa Fluor 488 secondary antibody (Molecular Probes,
Eugene, OR) was applied to the sections at 1:1000 for 1 hour at room
temperature and again washed. All myocytes and tissue sections were
mounted in Vectashield (Vector Labs, Peterborough, UK). The intensity of
the fluorescent antibody complex with K2p3.1 protein was measured by
laser scanning microscopy using an LSM5 Pascal Zeiss confocal
microscope equipped with a ×40 objective and set to collect light from
a 1µm optical slice (Zeiss, Oberkochen, Germany). Image stacks of the
entirety of individual myocytes were collected for analysis.
Quantification of K2p3.1 protein byWestern blot analysis was carried
out as previously described by Jones et al.10 In brief, tissue samples were
crushed under liquid nitrogen, suspended in protease inhibiting buffer
and centrifuged at 12 000 rpm for 10minutes at 4°C (Eppendorf,
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Stevenage, UK). The pellet was discarded and the cell lysate protein
content determined using a bicinchoninic acid assay (Pierce, Waltham,
MA). Samples (50 µg protein/lane) were separated by 10% sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS‐PAGE) electro-
phoresis and transferred to nitrocellulose membranes by semidry
discontinuous blotting (Pharmacia, Buckinghamshire, UK). Nonspecific
binding sites on the membrane were blocked by incubation overnight at
4°C in SuperBlock (Pierce). Anti‐K2p3.1 was applied (1:1000) in blocking
solution overnight at 4°C. Membranes were washed in Tween 20 (0.05%)
—PBS. The membrane was incubated with a secondary anti‐rabbit
antibody conjugated to horseradish peroxidase (HRP) (DAKO, Santa
Clara, CA) for 2 hours in blocking solution, then washed. The membrane‐
bound complex of K2p3.1 protein and antibody were detected as a band
at 130 kDa. by the ECL system (Pierce) using hyperfilm (GE Healthcare,
Amersham, UK). The procedure was repeated on the same membrane
using an anti‐desmin antibody (Sigma‐Aldrich, Dorset, UK) and secondary
anti‐mouse antibody conjugated to HRP (DAKO). The antibody complex
was identified as a specific band at 53 kDa and the band integrated signal
per sample used to verify equal protein loading of tissue.
2.3 | Detection of mRNA expression
Total RNA was extracted from subendocardial and subepicardial layers
using the Gen Elute extraction kit (Sigma‐Aldrich). Reverse transcription
was performed on 1 µg of total RNA per sample. Polymerase chain
reaction (PCR) was conducted on the ensuing reverse‐transcribed
material with 10 pmol of each primer, 20mM Tris pH 8.8, 10mM KCl,
10mM (NH4)2SO4, 2mM MgSO4, 0.1% Triton X‐100, 100 µg/mL
bovine serum albumin and 200 nM dNTPs. Using a Geneamp 2400
cycler (PE Biosystems, Waltham, MA) a “hot‐start” was initiated and
2.5U Taq DNA polymerase added: there were 30 cycles of PCR (94°C
30 seconds; 60°C 45 seconds; 72°C 30 seconds). The two sets of specific
primer pairs used were rat K2p3.1 5′‐ACGATGAAGCGGCAGAATGT
G‐3′ (sense) with 5′‐ACGAAACCGATGAGCCATG‐3′ (antisense) and
β‐actin 5′‐TTGTAACCAACTGGGACGATATGGG‐3′ (sense) with
5′‐GATCTTGATCTTCATGGTGCTAGG‐3′ (antisense). All conditions,
solutions, and primers are as previously described by Jones et al.10
2.4 | Electrophysiological recordings
The method for recording K2p3.1 currents was adapted from Besana
et al.19 Subepicardial or subendocardial myocytes were initially super-
fused at room temperature with a Tyrode’s buffer, containing (mM):
NaCl, 140; KCl, 5.4; MgCl2, 1; glucose, 10; HEPES, 5; CaCl2, 1; adjusted to
pH 7.4 using NaOH. Whole‐cell patch clamp was performed using glass
microelectrodes with a tip resistance of 4 to 6MΩ filled with a pipette
solution containing (mM): L‐aspartic acid, 146; KOH, 130; NaCl, 10;
EGTA, 5; HEPES, 10; MgATP, 2; CaCl2, 2; adjusted to pH 7.2 using KOH.
K2p3.1 current was recorded in modified Tyrode’s solution containing
(mM): NaCl, 100; KCl, 50; MgCl2, 1; HEPES, 5; glucose, 10; tetra-
ethylammonium chloride, 1; CsCl, 5; CaCl2, 1, adjusted to pH 7.4 using
NaOH. Cells were held at −10 mV in the presence of the high K+ solution
and allowed to equilibrate for 6minutes before measuring currents.
R(+)‐Methanandamide (Sigma‐Aldrich), a selective inhibitor of the
K2p3.1 channel, was dissolved in ethanol (5mg/mL), and further diluted
to a final working concentration of 10 µM. To selectively identify
current through K2p3.1 channels, a 6 second voltage ramp protocol from
−50 to 30mV was performed in the presence and absence of the
channel inhibitor with the difference current determined by subtraction.
Cell capacitance was assessed using 10mV hyperpolarizing pulses from
a holding potential of −80mV. Recordings were made using an
Axopatch 200B amplifier (Molecular Devices, San Jose, CA) with
digital/analog conversion via a Digidata 1322 interface (Molecular
Devices). During K2p3.1 current recordings whole‐cell capacitance was
compensated and series‐resistance compensation was typically 70% to
75%. Data were acquired at 5 kHz with a low pass Bessel filter of 1 kHz.
2.5 | Analysis of data
Immunofluorescent images of sections and single myocytes were
taken using identical settings. Fluorescence intensity profiles of 10
microns width were taken perpendicular to the epicardial and
endocardial surfaces across the ventricular wall. Average intensities
of fluorescence were calculated for each 20% of the distance across
the total transmural distance of the left ventricular free wall from the
subepicardium to the subendocardium. The collective data for each
interval were normalized to the fluorescence intensity of the first
subepicardial interval (0%‐20% of the distance across the wall).
Electrophysiological data were analyzed using Clampfit 9
(Molecular Devices). Records were not corrected for the liquid
junctional potential that was measured to be −9.8mV. Peak current
density comparisons were made at 30mV. Current density measure-
ments were expressed relative to the whole‐cell capacitance, which
was determined as the integral of the whole‐cell capacitance
transient. IK2p3.1 was taken as the methanandamide‐sensitive current.
2.6 | Statistical analysis
Data are expressed as means ± standard error of the mean (SEM) and
n = number in the group. A minimum of six animals were used per
experimental grouping (n), corresponding to protein/tissue samples
or electrophysiology results as appropriate. For the tissue cross‐
sectional analysis, 6 to 8 sections were taken at distributed points
down the left ventricular wall as obtained from seven animals.
Statistical assessment was performed by two‐way Student's t test or
one‐way analysis of variance with Holm‐Sidak post hoc comparisons,
as appropriate. Significance was determined if P < 0.05.
3 | RESULTS
3.1 | K2p3.1 protein expression in single myocytes
isolated from subepicardial and subendocardial layers
of the rat left ventricle
Specificity of the antibody to C‐terminal K2p3.1 protein for use in
immunofluorescence with confocal microscopy was previously
JONES ET AL. | 385
determined by Jones et al.10 In the present study, myocytes
isolated from subepicardial tissue exhibited visibly less labelled
K2p3.1 protein than those isolated from the subendocardial
tissue; both cell types exhibited a similar pattern of strong
staining at the intercalated disc with transversely oriented
fluorescence striations consistent with t‐tubules across the
myocyte (Figure 1A). The individual projected area of cells from
each region was determined and did not differ significantly
between regions (Figure 1B; n = 92). At mid‐cell depth, a single
optical slice was used to assess the density of channel expression.
Myocytes isolated from the subendocardial region demonstrated
a two‐fold greater integrated fluorescence of labelled K2p3.1
protein (205% ± 13.5%) compared with the signal from myocytes
from the subepicardial region (100% ± 5.3%) (Figure 1C; n = 92
cells per group; P < 0.0001). This significant difference of
immunofluorescence was maintained when the signal was
expressed relative to cell cross‐sectional area (Figure 1D; n = 92
cells per group; P < 0.0001). As such, using this method total and
density of K2p3.1 protein expression were determined to be
higher in cells from the subendocardial region compared with
those from the subepicardial region.
3.2 | A transmural gradient of K2p3.1 protein
expression across the left ventricular free wall
Ventricular tissue exhibited the same pattern of labelled K2p3.1
protein as previously observed in myocytes with strong labelling of
transverse striations across each myocyte and also present at the
intercalated disc (Figure 2A). The regional distribution of immuno-
fluorescent labelled K2p3.1 protein was determined across the left
ventricular free wall. The profile of immunofluorescent labelled
K2p3.1 protein intensity showed a progressive increase towards the
endocardial surface. Immunofluorescence was averaged for each
20% interval distance along the profile from the epicardium for each
section (Figure 2B and 2C). Significantly greater fluorescence was
detected in the most endocardial segment at 80% to 100% of the
transmural distance (171% ± 7.7% endocardial layer) compared with
the initial epicardial 0% to 20% of the distance (100% ± 5.3%
epicardial layer). Similar significant differences were noted when
the 0% to 20% interval distance was compared with the 60% to 70%
distance interval (130% ± 6.4%) and 80% to 90% distance interval
(166% ± 8.7%) (Figure 2D) (n = 49 sections; one‐way analysis of
variance with Holm‐Sidak comparisons *P < 0.001).
F IGURE 1 Single epicardial and
endocardial myocytes immunofluorescent
label of K2p3.1 protein. A, Illustrative
example high‐resolution images of K2p3.1
protein labelling in single myocytes from the
subepicardial (left) and subendocardial
(right) regions of the left ventricle. B, Single
myocyte cross‐sectional area for cells from
each region. C, Mean total
immunofluorescence of labelled K2p3.1
protein per myocyte. D, The mean density of
immunofluorescence of labelled K2p3.1
protein (each panel shows means ± SEM;
n = 92 cells per group; bars denote
significant differences by t test; *P < 0.001)
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3.3 | Quantification of K2p3.1 protein expression
and mRNA in tissue isolated from subendocardial and
subepicardial regions
The expression of K2p3.1 protein, as assessed by Western blot analysis,
was identified as a specific protein band with a molecular weight of
130 kDa in each lane of ventricular tissue (Figure 3A). We have
previously shown this specific band to be absent when the anti‐K2p3.1
antibody is competitively inhibited with the appropriate antigenic K2p3.1
peptide.10 Furthermore, no bands were observed after omission of the
primary anti‐K2p3.1 antibody. The integrated signal from the labelled
K2p3.1 protein was normalized to that for labelled desmin protein as
identified per tissue sample lane. Our assessment of the relative density
of labelled K2p3.1 protein showed that tissue from the subendocardial
region possessed more than 50% more K2p3.1 protein than tissue from
the subepicardial region (157%±2.6% vs 100%±5.0%, respectively;
Figure 1A; n=8; P <0.0001).
In contrast, analysis of K2p3.1 mRNA expression found there
was no significant difference in mRNA content of the myocardium
F IGURE 2 Transmural gradient of immunofluorescent‐labelled K2p3.1 protein expressed across the left ventricular free wall. A, Illustrative
high‐resolution image of myocytes within the left ventricular wall with K2p3.1 protein labelled. B, Example of K2p3.1 protein labelling in a cross‐
section of the left ventricular free wall. B‐C, A white dashed line is oriented perpendicular to the epicardial surface and is drawn to the
endocardial surface in (B), which indicates the line used to determine a transmural profile of immunofluorescent labelled K2p3.1 protein in (C).
C, A profile of fluorescence from an example tissue section shows the increase in immunofluorescent‐labelled K2p3.1 protein from the epicardial
surface to the endocardial surface across the left ventricular free wall. D, Intensity of labelled K2p3.1 protein (n = 49) compared at 20% distance
intervals across the left ventricular wall. Mean values were normalized to signal in the most epicardial interval (0%‐20% distance across the left
ventricular wall). Data are shown as means ± SEM; n = 49 sections per group; one‐way analysis of variance with Holm‐Sidak comparisons
*P < 0.001
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between the subendocardial and subepicardial layers (1.88 ± 0.2
mRNA transcript expression vs 2.06 ± 0.4, respectively; Figure 3B;
n = 10).
3.4 | Regional differences in K2p3.1 current
We have determined a transmural gradient of protein expression but
this does not automatically indicate a functional difference across the
ventricular wall. Currents recorded using a slow ramp protocol
(−50 to 30mV over 6 seconds) showed a methanandamide‐sensitive
component to the current‐voltage relationship (shown in Figure 4)
typical of an open rectifying current with a reversal potential at
−10 mV (−19.8mV when corrected for the junction potential).
Current‐voltage relationships in myocytes from both the
subepicardial and subendocardial layers displayed similar rectifica-
tion. Overall, a significantly larger current density was measured in
myocytes from the subendocardial region (7.66 ± 0.53 pA/pF; n = 7)
in comparison with myocytes from the subepicardial region
(3.47 ± 0.74 pA/pF; n = 6; Figure 4E; *P < 0.001). On average the
current density in myocytes from the subendocardial layer was more
than double that identified in cells from the subepicardial region.
4 | DISCUSSION
K2p3.1 mRNA and protein have been identified in both the atria and
ventricles of the rat and human heart alike.10,20,21 In the present
study we have refined this understanding confirming K2p3.1
expression extensively throughout the rat left ventricle, producing
a significant open‐rectifying potassium current in myocytes isolated
from both the subepicardial and subendocardial regions. However,
K2p3.1 protein is expressed heterogeneously across the left
ventricular wall with less than half the K2p3.1 current being identified
in myocytes from the subepicardial region compared with that
measured in myocytes from the subendocardial region. This despite a
lack of differential expression of the encoding mRNA implying
differences in translational regulation, trafficking or turnover of this
channel. The identified heterogeneity of this channel, with a key role
to play in moderating the action potential during normal physiology
but particularly during pathophysiology, is of interest in determining
the potential causes of arrhythmias, particularly during and post
myocardial infarction.
The cardiac action potential displays characteristics that are
distinct for each region of the healthy heart.22 The key difference in
the action potential profiles across the left ventricular wall is the rate
of repolarization, which occurs more rapidly in the subepicardial
region of the left ventricle than the subendocardial region, principally
due to heterogeneity in expression of key potassium channels.23 We
have now identified significant differences in IK2p3.1, adding to our
understanding of the heterogeneity of K+ channel expression.3,8
Previous measures by Putzke et al16 showed K2p3.1 to be responsible
for between 3% and 40% of net outward current at 0mV. If these
measures represent the range of contributions of this channel to
action potential forms in this mixed population of myocytes from
across the left ventricle to repolarization the impact of the identified
heterogeneity on the dispersion of repolarization is of key
significance. Indeed, using a model of a subepicardial myocyte Putzke
et al16 showed inhibition of K2p3.1 channels to effect a 12% to 14%
prolongation of the APD. Our data now show that expression and
function of this channel is actually lowest in this region with an
approximate doubling of current density in cells from the subendo-
cardial region. As such, channel modulation is predicted to have an
even greater impact in myocytes from the subendocardial region.
Given that myocytes from the subendocardial region already have
longer APD compared with those from the subepicardial region,
inhibition of K2p3.1 channels is therefore likely to further exacerbate
this difference increasing dispersion of repolarization.
F IGURE 3 Quantification of K2p3.1 protein and mRNA
expression. A, An example of a Western blot showing the identified
specific single band labelled for K2p3.1 protein (and desmin protein
band for normalization). Significantly more K2p3.1 protein was
expressed in tissue from the subendocardial than the subepicardial
layer (mean ± SEM; n = 8; Student’s t test *P < 0.0001). B, No
significant difference in the amount of K2p3.1 mRNA as expressed
relative to GAPDH mRNA was identified between regions
(mean ± SEM; n = 10). GAPDH, glyceraldehyde 3‐phosphate
dehydrogenase; mRNA, messenger RNA
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Inhibition of IK2p3.1 is known to promote spontaneous activity and
prolong the cardiac action potential, leading to early after depolar-
izations (EADs) and spontaneous ectopic activity creating a substrate
for ventricular arrhythmia.8 Factors that modulate K2p3.1 can arise
as a result of an ischaemic insult with local accumulation of hydrogen
ions being the most notable acute inhibitor under such condi-
tions.3,19,24 The high sensitivity of K2p3.1 to extracellular pH in the
physiological range leads to potentially complete current inhibition in
the event of a regional or global ischemic insult. Even modest acidosis
under low‐flow or complete ischemia will significantly reduce the
current through this channel prolonging the APD and predisposing to
EADs. Also associated with ischaemic insults is inflammation and the
rapid activation of leukocytes that release platelet activating factor
(PAF).25 This release of PAF in the heart is associated with APD
prolongation and EADs and arrhythmias.26 The mechanism for this
action is by inhibition of K2p3.1 resulting in action potential
abnormalities as previously demonstrated in mouse and canine
ventricular myocytes.8,19,26 We now propose this effect is com-
pounded by the heterogeneous nature of the expression of K2p3.1
channels, which, therefore, is likely to create a marked increase in
action potential heterogeneity during and immediately post myocar-
dial infarction. An issue further compounded by the fact acidosis and
ischemia is often itself be heterogeneous in nature with the
subendocardial region commonly showing greater changes and
frequency of issues than the subepicardial region.
While the rat heart differs considerably from the human in terms
of size, rate and shape of the cardiac action potential, it remains one
of the most widely used models used to study cardiac function, and,
in particular, cardiac heterogeneity. Qualitatively, there are simila-
rities in apparent electrical heterogeneity across the left ventricular
F IGURE 4 K2p3.1 Current‐voltage relationship in the left ventricular free wall. Subepicardial and subendocardial layer–derived myocytes
were whole‐cell voltage‐clamped. A, Cells were voltage‐ramped from −50 to 30mV over 6 seconds with a holding potential of −10 mV (upper
line, black), whole‐cell currents were recorded (lower line, red). B, Current‐voltage relationship in the presence (met) and absence (control) of a
specific K2p3.1 inhibitor methanandamide. C, Example of the methanandamide‐sensitive current‐voltage relationship from a single ventricular
myocyte. D, Current‐voltage relationship from epicardial and endocardial myocytes. E, Average currents at 30mV, taken as the peak outward
current, were shown in the endocardial myocyte to be double that measured in the epicardial myocyte (Students t test, *P < 0.001; Epi n = 7;
Endo n = 6)
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wall between rats and humans with differences in action potential
duration between the subendocardial and subepicardial region
present in both species, and in each case associated with regional
differences in potassium currents. A key difference between rats and
humans is the duration that potassium currents act in terms of
impacting repolarization. The rat action potential is quick (several to
10 seconds of msec in duration depending on heart rate) and this
means only rapidly acting currents with a relatively large capacity for
ion flux can significantly alter action potential duration. In contrast,
the longer human action potential (100 seconds of msec in duration)
gives scope for smaller and slower activating fluxes to influence
action potential duration. As such, the impact of IK2p3.1and modera-
tion of this component could potentially be greater in humans than
the rat heart. A potential indicator of this proposed role is the fact
that the volatile anesthetic sevoflurane, known to activate K2p3.1
channels, precipitates increased dispersion of repolarization in the
human heart, an indicator of increasing action potential hetero-
geneity across the ventricular wall.27 Such an effect may be due, at
least in part, to a comparable heterogeneous distribution of K2p3.1
channel expression in the human heart to that which we have now
documented in the rat, although future analysis of human ventricular
samples would be required to confirm this.
K2p3.1 channels have previously had limited investigation with
respect to clinical issues and outcomes in the ventricle of the heart but
the heterogeneity of K2p3.1 expression and activity has implications for
understanding pharmacology of several commonly used agents. One of
the most commonly used class III antiarrhythmia drugs, amiodarone has
an inhibitory effect on K2p3.1,
28 as do α1 adrenergic agonists.4 The
heterogeneous impact and prolonging effect on the cardiac APD under
some conditions may be antiarrhythmogenic, but the implications are
that by extension of the effects seen with PAF and other blockers they
could also be proarrhythmogenic. Indeed, even amiodarone has been
shown to be proarrhythmic in several cases (eg, Stanton et al29),
although its polygenic actions complicating direct interpretation of
mechanism actions on K2p3.1 could be key. In contrast to the numerous
agents that can inhibit K2p3.1, inhalational anesthetics such as
sevoflurane and isoflurane at clinically relevant concentrations can
activate human K2p3.1 causing significant APD shortening. As men-
tioned above such effects appear to have a heterogeneous impact,
which fits with the current data and has the potential to contribute to
arrhythmia formation.4,27 Such impacts are, however, complex to
interpret, particularly under conditions of cardiac surgery and where
other interactions with local and circulating inhibitory factors are
occurring.
5 | CONCLUSION
In conclusion, a transmural gradient of K2p3.1 protein expression
exists across the left ventricular wall with expression increasing
from the epicardial to the endocardial surface. This transmural
gradient of K2p3.1 function is likely to contribute to electrical
stability of the left ventricular wall, while being highly susceptible
to physiological and pharmacological modulation that can pro-
mote arrhythmogenesis.
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